Factor Xa
Fxa
Factor Xa, a trypsin-like serine protease, is situated at the critical juncture between the intrinsic and extrinsic pathways, catalyzing the conversion of prothrombin to thrombin, and hence plays a pivotal role in the final common pathway of the cascade and has become an important target in the discovery and development of new anticoagulants. Factor Xa is a key protease of the coagulation pathway whose activity is known to be in part modulated by binding to factor Va and sodium ions.
Blood coagulation involves a complex cascade of enzymatic reactions, ultimately generating fibrin, the basis of all blood clots. This cascade is comprised of two arms, the intrinsic and extrinsic pathways which converge at factor Xa to form the common pathway. Factor Xa activates prothrombin to thrombin, which in turn catalyzes the conversion of fibrinogen to fibrin.
All Product Categories
-
Factor Xa Related Products (168)
Related Products (168)
-
Antibodies (1)
-
EMD 495235
0 ImagesCat. No.: HY-10777CAS No.: 811811-33-3EMD 495235 is a potent and orally active coagulation factor Xa inhibitor with an IC50 of 5.5 nM and a Ki of 6.8 nM. EMD 495235 shows anticoagulant activities.
-
Naroparcil
0 ImagesCat. No.: HY-105919CAS No.: 120819-70-7Naroparcil is an orally active antithrombotic agent. Naroparcil exhibits antithrombotic effects in rabbit Wessler stasis model with EC50s of 21.9 mg/kg and 36.0 mg/kg after respectively intravenous injection and oral administration.
-
FXIa-IN-16
0 ImagesCat. No.: HY-172400CAS No.: 3046390-69-3FXIa-IN-16 is an orally active selective FXIa inhibitor with an IC50 of 0.19 nM. FXIa-IN-16 exerts highly selective competitive inhibition on endogenous FXIa, blocks the thrombin amplification loop to inhibit thrombosis, while preserving exogenous physiological hemostatic function. FXIa-IN-16 can be used in thrombosis-related research.
-
Coumafuryl-d3
0 ImagesCat. No.: HY-121244SCoumafuryl-d3 is the deuterium labeled Coumafuryl (HY-121244). Coumafuryl is a kind of coumarin rodenticide. Coumafuryl inhibits the metabolic cycle of vitamin K that causes the interference with protein biosynthesis of vitamin K-dependent coagulant factors (II, VII, IX, and X factors) in the liver.
-
FXIa-IN-10
0 ImagesCat. No.: HY-151196CAS No.: 2816108-08-2FXIa-IN-10 (Compound 3f) is a potent activated factor XI (FXIa) inhibitor with an Ki of 0.17 nM. FXIa-IN-10 has good oral bioavailability.
-
Canine Factor Xa
0 ImagesCanine Factor Xa is a serine protease that plays a central role in blood coagulation, with prothrombin as its physiological substrate. Canine Factor Xa catalyzes the conversion of prothrombin to thrombin, activates factor VIII, and hydrolyzes peptide, thioester, and amide substrates. Canine Factor Xa cleaves protease-activated receptors 1 and 2 to activate intracellular signal transduction. Canine Factor Xa regulates multiple cellular pathways, mediates various cellular activities, tissue remodeling and cancer cell migration, and inhibits apoptosis in some cancer cells. Canine Factor Xa protects hippocampal neurons against glutamate-induced damage. Canine Factor Xa participates in embryonic vascular development and regulates immune hematopoiesis; its activity is inhibited by soybean trypsin inhibitor, and cannot be enhanced by phospholipids. Canine Factor Xa regulates immune responses and macrophage polarization, and participates in fibrosis, vascular remodeling and tumor progression through non-coagulant effects. Canine Factor Xa can be used in research related to atherosclerosis, fibrosis, asthma, cancer, thromboinflammation, sepsis, etc.
-
FAM labled Fitusiran sodium
0 ImagesCat. No.: HY-132587DFAM labled Fitusiran sodiumis a FAM labled Fitusiran sodium (HY-132587A). Fitusiran (ALN-AT3SC) sodium is a siRNA strategy. Fitusiran delivers siRNA targeting the SERPINC1 gene in hepatocytes to inhibit antithrombin synthesis. Fitusiran sodium enhances thrombin activity and increases Thrombin generation, thereby restoring hemostatic function. Fitusiran sodium can be used in hemophilia-related research.
-
FXIa-IN-6
0 ImagesCat. No.: HY-145349CAS No.: 1551459-37-0FXIa-IN-6 is a potent FXIa inhibitor with selectivity against most of the relevant serine proteases (Ki = 0.3 nM).
-
Methoxycarbonyl-D-Nle-Gly-Arg-pNA
0 ImagesCat. No.: HY-P4576CAS No.: 104186-68-7Methoxycarbonyl-D-Nle-Gly-Arg-pNA is a synthetic trypsin that can serve as a substrate for coagulation factors IXa (FIXa) and Xa (FXa).
-
DX-9065a
0 ImagesCat. No.: HY-10722CAS No.: 155204-81-2DX-9065a is a selective, nonpeptidic, and orally active factor Xa (FXa) inhibitor with a Ki of 41 nM for human FXa. DX-9065a has low activity against other serine proteases. DX-9065a has strong anticoagulant actions.
-
DPC423
0 ImagesCat. No.: HY-11090ACAS No.: 292135-59-2DPC423 is a selective and orally active factor Xa inhibitor with a Kis of 0.15 (human) and 0.3 (rabbit) nM. DPC423 exhibits Kis of 60, 61 and 6000 nM against human trypsin, plasma kallikrein and thrombin. DPC423 blocks the formation of prothrombinase complex, reduces thrombin production, inhibits fibrin formation and platelet activation. DPC423 can be used for the study of anticoagulation of arterial thrombosis.
-
Cy3 labled Fitusiran sodium
0 ImagesCat. No.: HY-132587ECy3 labled Fitusiran sodium is a Cy3 labled Fitusiran sodium (HY-132587A). Fitusiran (ALN-AT3SC) sodium is a siRNA strategy. Fitusiran delivers siRNA targeting the SERPINC1 gene in hepatocytes to inhibit antithrombin synthesis. Fitusiran sodium enhances thrombin activity and increases Thrombin generation, thereby restoring hemostatic function. Fitusiran sodium can be used in hemophilia-related research.
-
Anivamersen
0 ImagesCat. No.: HY-153836CAS No.: 959716-29-1Anivamersen is an RNA aptamer to reverse the anticoagulant effect of the parenteral factor IXa inhibitor pegnivacogin. REG1 is a novel anticoagulation system consisting of pegnivacogin, an RNA aptamer inhibitor of coagulation factor IXa, and anivamersen, a complementary sequence reversal oligonucleotide.
-
LY-517717
0 ImagesCat. No.: HY-10269CAS No.: 313489-71-3LY-517717 is a potent and orally active FXa inhibitor. LY-517717 shows antithrombotic and anticoagulant activity. LY-517717 has the potential for the research of venous thromboembolism after hip or knee replacement.
-
BI-11634
0 ImagesCat. No.: HY-125505CAS No.: 1622159-00-5BI-11634 is an orally active factor Xa inhibitor and a CYP3A4 substrate. The apparent Km values for BI-11634 metabolism are 23 μM in human liver microsomes (HLMs) and 7.6 μM with recombinant CYP3A4. BI-11634 can be used for thromboembolic disease and CYP3A4-mediated drug metabolism research.
-
Pegnivacogin sodium
0 ImagesCat. No.: HY-153835APegnivacogin sodium is a novel RNA-aptamer based factor IXa inhibitor featuring a reversal agent, anivamersen.
-
Fondaparinux sodium (Standard)
0 ImagesCat. No.: HY-B0597RCAS No.: 114870-03-0Synonyms: Fondaparin sodium (Standard); SR-90107A (Standard)Fondaparinux (sodium) (Standard) is the analytical standard of Fondaparinux (sodium). This product is intended for research and analytical applications. Fondaparinux sodium is an antithrombin-dependent factor Xa inhibitor.
-
Rat Factor Xa
0 ImagesRat Factor Xa is a serine protease that plays a central role in blood coagulation, with prothrombin as its physiological substrate. Rat Factor Xa catalyzes the conversion of prothrombin to thrombin, activates factor VIII, and hydrolyzes peptide, thioester, and amide substrates. Rat Factor Xa cleaves protease-activated receptors 1 and 2 to activate intracellular signal transduction. Rat Factor Xa regulates multiple cellular pathways, mediates various cellular activities, tissue remodeling and cancer cell migration, and inhibits apoptosis in some cancer cells. Rat Factor Xa protects hippocampal neurons against glutamate-induced damage. Rat Factor Xa participates in embryonic vascular development and regulates immune hematopoiesis; its activity is inhibited by soybean trypsin inhibitor, and cannot be enhanced by phospholipids. Rat Factor Xa regulates immune responses and macrophage polarization, and participates in fibrosis, vascular remodeling and tumor progression through non-coagulant effects. Rat Factor Xa can be used in research related to atherosclerosis, fibrosis, asthma, cancer, thromboinflammation, sepsis, etc.
-
FXIa-IN-13
0 ImagesCat. No.: HY-153817CAS No.: 2629361-99-3FXIa-IN-13 (example 1) is an Factor Xa inhibitor with antithrombotic activity. FXIa-IN-13 inhibits arteriovenous thrombosis in vivo and in vitro.
-
FXa-IN-1
0 ImagesCat. No.: HY-10758CAS No.: 441328-10-5FXa-IN-1 is a FXa inhibitor (IC50: 3 nM, Ki: 0.7 nM) with respectable oral bioavailability and half-life in vivo. FXa-IN-1 can be used for thromboembolic disorders.
